These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22549638)

  • 1. Bisphosphonates: focus on inflammation and bone loss.
    Iannitti T; Rosini S; Lodi D; Frediani B; Rottigni V; Palmieri B
    Am J Ther; 2012 May; 19(3):228-46. PubMed ID: 22549638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra-skeletal effects of bisphosphonates.
    Corrado A; Santoro N; Cantatore FP
    Joint Bone Spine; 2007 Jan; 74(1):32-8. PubMed ID: 17196868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bisphosphonates: indications in bone diseases other than osteoporosis].
    Abdelmoula LC; Ben M'barek R; Ben Hadj Yahia C; Tekaya R; Testouri N; Chaabouni L; Zouari R
    Tunis Med; 2011 Jun; 89(6):511-6. PubMed ID: 21681711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: mechanism of action and role in clinical practice.
    Drake MT; Clarke BL; Khosla S
    Mayo Clin Proc; 2008 Sep; 83(9):1032-45. PubMed ID: 18775204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials with bisphosphonates.
    Lombardi A; Santora AC
    Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy.
    Su K; Shi X; Varshney RR; Wang DA
    Expert Opin Drug Deliv; 2011 Jan; 8(1):113-26. PubMed ID: 21174607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates.
    Masaike Y; Takagi T; Hirota M; Yamada J; Ishihara S; Yung TM; Inoue T; Sawa C; Sagara H; Sakamoto S; Kabe Y; Takahashi Y; Yamaguchi Y; Handa H
    Mol Pharmacol; 2010 Feb; 77(2):262-9. PubMed ID: 19903825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, clinical development, and therapeutic uses of bisphosphonates.
    Licata AA
    Ann Pharmacother; 2005 Apr; 39(4):668-77. PubMed ID: 15755793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
    Ikeda K; Fukagawa M
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
    [No Abstract]   [Full Text] [Related]  

  • 14. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats.
    Aspenberg P; Wermelin K; Tengwall P; Fahlgren A
    Acta Orthop; 2008 Feb; 79(1):111-5. PubMed ID: 18283582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.